Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome

doi:10.1084/jem.178.6.2097

This Article

	Full Text (PDF, 1770K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Butler, M. H.
	Articles by De Camilli, P.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Butler, M. H.
	Articles by De Camilli, P.


Social Bookmarking

	What's this?

ARTICLES

Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome

MH Butler, M Solimena, R Dirkx Jr, A Hayday and P De Camilli
Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut 06510.

Glutamic acid decarboxylase (GAD) is the enzyme that synthesizes the neurotransmitter gamma-aminobutyric acid (GABA) in neurons and in pancreatic beta cells. It is a major target of autoimmunity in Stiff- Man syndrome (SMS), a rare neurological disease, and in insulin- dependent diabetes mellitus. The two GAD isoforms, GAD-65 and GAD-67, are the products of two different genes. GAD-67 and GAD-65 are very similar to each other in amino acid sequence and differ substantially only at their NH2-terminal region. We have investigated the reactivity of autoantibodies of 30 Stiff-Man syndrome patients to GAD. All patient sera contained antibodies that recognize strongly GAD-65, but also GAD- 67, when tested by immunoprecipitation on brain extracts and by immunoprecipitation or immunocytochemistry on cells transfected with either the GAD-65 or the GAD-67 gene. When tested by Western blotting, all patient sera selectively recognized GAD-65. Western blot analysis of deletion mutants of GAD-65 demonstrated that autoantibodies are directed predominantly against two regions of the GAD-65 molecule. All SMS sera strongly recognized a fragment contained between amino acid 475 and the COOH terminus (amino acid 585). Within this region, amino acids 475-484 and 571-585 were required for reactivity. The requirement of these two discontinuous segments implies that the epitope is influenced by conformation. This reactivity is similar to that displayed by the monoclonal antibody GAD 6, suggesting the presence of a single immunodominant epitope (SMS-E1) in this region of GAD-65. In addition, most SMS sera recognized at least one epitope (SMS-E2) in the NH2-terminal domain of GAD-65 (amino acids 1-95). The demonstration in SMS patients of a strikingly homogeneous humoral autoimmune response against GAD and the identification of dominant autoreactive target regions may help to elucidate the molecular mechanisms of GAD processing and presentation involved in GAD autoimmunity. Moreover, the reactivity reported here of GAD autoantibodies in SMS partially differs from the reactivity of GAD autoantibodies in insulin-dependent diabetes mellitus, suggesting a link between the pattern of humoral autoimmunity and the clinical condition.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Mayr, A., Schlosser, M., Grober, N., Kenk, H., Ziegler, A. G., Bonifacio, E., Achenbach, P. (2007). GAD Autoantibody Affinity and Epitope Specificity Identify Distinct Immunization Profiles in Children at Risk for Type 1 Diabetes. Diabetes 56: 1527-1533 [Abstract] [Full Text]
Achenbach, P., Warncke, K., Reiter, J., Naserke, H. E., Williams, A. J.K., Bingley, P. J., Bonifacio, E., Ziegler, A.-G. (2004). Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics. Diabetes 53: 384-392 [Abstract] [Full Text]
Kobayashi, T., Tanaka, S., Okubo, M., Nakanishi, K., Murase, T., Lernmark, A. (2003). Unique Epitopes of Glutamic Acid Decarboxylase Autoantibodies in Slowly Progressive Type 1 Diabetes. J. Clin. Endocrinol. Metab. 88: 4768-4775 [Abstract] [Full Text]
Dalakas, M. C., Li, M., Fujii, M., Jacobowitz, D. M. (2001). Stiff person syndrome: Quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 57: 780-784 [Abstract] [Full Text]
Meinck, H-M, Faber, L, Morgenthaler, N, Seissler, J, Maile, S, Butler, M, Solimena, M, DeCamilli, P, Scherbaum, W. (2001). Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases. J. Neurol. Neurosurg. Psychiatry 71: 100-103 [Abstract] [Full Text]
Abraham, R. S., Wen, L., Marietta, E. V., David, C. S. (2001). Type 1 Diabetes-Predisposing MHC Alleles Influence the Selection of Glutamic Acid Decarboxylase (GAD) 65-Specific T Cells in a Transgenic Model. J. Immunol. 166: 1370-1379 [Abstract] [Full Text]
Myers, M. A., Davies, J. M., Tong, J. C., Whisstock, J., Scealy, M., Mackay, I. R., Rowley, M. J. (2000). Conformational Epitopes on the Diabetes Autoantigen GAD65 Identified by Peptide Phage Display and Molecular Modeling. J. Immunol. 165: 3830-3838 [Abstract] [Full Text]
Peltola, J., Kulmala, P., Isojarvi, J., Saiz, A., Latvala, K., Palmio, J., Savola, K., Knip, M., Keranen, T., Graus, F. (2000). Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 55: 46-50 [Abstract] [Full Text]
Falorni, A., Gambelunghe, G., Forini, F., Kassi, G., Cosentino, A., Candeloro, P., Bolli, G. B., Brunetti, P., Calcinaro, F. (2000). Autoantibody Recognition of COOH-Terminal Epitopes of GAD65 Marks the Risk for Insulin Requirement in Adult-Onset Diabetes Mellitus. J. Clin. Endocrinol. Metab. 85: 309-316 [Abstract] [Full Text]
Levy, L. M., Dalakas, M. C., Floeter, M. K. (1999). The Stiff-Person Syndrome: An Autoimmune Disorder Affecting Neurotransmission of {gamma}-Aminobutyric Acid. ANN INTERN MED 131: 522-530 [Abstract] [Full Text]
Geng, L., Solimena, M., Flavell, R. A., Sherwin, R. S., Hayday, A. C. (1998). Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate disease. Proc. Natl. Acad. Sci. USA 95: 10055-10060 [Abstract] [Full Text]
Hummel, M, Durinovic-Bello, I, Bonifacio, E, Lampasona, V, Endl, J, Fessele, S, Bergh, F T., Trenkwalder, C, Standl, E, Ziegler, A-G (1998). Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus. J. Neurol. Neurosurg. Psychiatry 65: 204-208 [Abstract] [Full Text]
Ringstad, N., Nemoto, Y., De Camilli, P. (1997). The SH3p4/Sh3p8/SH3p13 protein family: Binding partners for synaptojanin and dynamin via a Grb2-like Src homology 3�domain. Proc. Natl. Acad. Sci. USA 94: 8569-8574 [Abstract] [Full Text]
Tremble, J., Morgenthaler, N. G., Vlug, A., Powers, A. C., Christie, M. R., Scherbaum, W. A., Banga, J. P. (1997). Human B Cells Secreting Immunoglobulin G to Glutamic Acid Decarboxylase-65 from a Nondiabetic Patient with Multiple Autoantibodies and Graves' Disease: A Comparison with Those Present in Type 1 Diabetes. J. Clin. Endocrinol. Metab. 82: 2664-2670 [Abstract] [Full Text]
Dirkx, R. Jr., Thomas, A., Li, L., Lernmark, �k., Sherwin, R. S., De Camilli, P., Solimena, M. (1995). Targeting of the 67-kDa Isoform of Glutamic Acid Decarboxylase to Intracellular Organelles Is Mediated by Its Interaction with the NH(2)-terminal Region of the 65-kDa Isoform of Glutamic Acid Decarboxylase. J. Biol. Chem. 270: 2241-2246 [Abstract] [Full Text]